Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Sygnis Pharma
Sygnis Pharma
Activities:
Research & Development
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Analysis
SYGNIS AG announces the launch of TrueHelix
The first tool on the TrueHelix platform addresses sample contamination, a key pitfall in NGS workflows
Ingredients
SYGNIS AG reinforces its proteomics portfolio with two patents granted in Europe and China
Granted patents confirm innovation and novelty of proteomics product range
Research & Development
Sygnis strengthens management team with appointment of Heikki Lanckriet
He joins the DNA amplification and sequencing firm as joint CEO and Chief Scientific Officer
Subscribe now